Great news from Ambrose as they continue to build out their portfolio. Having a 5.5% shareholding through ValiSeek as a result of our licensing deal for 401 means we benefit from value inflections in Ambrose as they build their asset base with approved orphan status candidates (both FDA and EMA). There has a so been a significant amount of investment and interest in the asset from big pharma albeit for an indication that ultimately didn't progress. Redirecting the asset to an orphan status indication with only a single pivotal study required really positions Ambrose for rapid translation of this asset. We believe the increase in our share price on the back of this news is a recognition of the value of our holding in Ambrose as just one of several asset classes we have inetrests in and look forward to providing further updates on the other assets including Cytolytix, the MG001 asset under discussion with McGill and progress with ValiRx animal Health.